Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration
- Institution
- BRIGHAM AND WOMEN'S HOSPITAL, MA
- Principal investigator
- Markus H. Frank
- Funding
- $365K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Project 3 will test the central hypotheses that (1) ABCB5(+) dermal mesenchymal stem cells (DMSC) are required for normal adult skin homeostasis and regeneration; (2) ABCB5(+) DMSC decline is responsible for impaired skin homeostasis and regenerative wound healing during aging; and (3) ABCB5(+) DMSC transplantation possesses therapeutic potential to restore age-related impairment of skin homeostasis and regeneration. The overall significance of this study are the potential shifts in research paradigms resulting from successful completion of this research: (1) The proposed experiments will answer a fundamental question in stem cell biology and aging that has not been addressed as-of-yet in prospective studies – To what extent is selective dysfunction in an adult stem cell compartment (vis-à-vis dysregulation of differentiated tissues) responsible for organismal aging?; and (2) Documentation of the regenerative capacity of ABCB5(+) DMSC along with demonstration of their decline as a cause age-related impairment of skin regenerative capacity will lay the foundation for targeted employment of this candidate cell therapeutic for the treatment of cutaneous wounds in aging patients.
LOADING MOONBASE SCORE
Questions for BRIGHAM AND WOMEN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston Children'S HospitalNot yet scored
ABCB5-positive stem cells for LSCD therapy
Markus H. Frank · $762K · 2016–2028
- NIH · Brigham and Women'S Hospital64
Making the invisible visible: An automated clinical decision support tool for Intimate Partner Violence Risk and Severity Prediction (AIRS)
Bharti Khurana · $796K · 2022–2027
- NIH · Brigham and Women'S Hospital60
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
Holly Elizabeth Rawizza · $190K · 2022–2028